Alumis Inc — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
EnvudeucitinibThe purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.	Lupus	Phase 2	À vérifier	United States, Argentina, Bulgaria, Chile, Colombia, Croatia, Denmark, Georgia, …	À vérifier
EnvudeucitinibThe purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.	Lupus	Phase 2	À vérifier	United States, Argentina, Bulgaria, Chile, Colombia, Croatia, Denmark, Georgia, Germany, Hungary, India, Mexico, Peru, Philippines, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, …	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Envudeucitinib	Lupus	Phase 2	NCT05966480	LUMUS — Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.